Accelerating Breakthrough Discoveries into Medicines

Perry B. Molinoff, MD, Chairman

Perry B. Molinoff, MD, Chairman, Innovation Support Center Advisory Panel

Perry B. Molinoff is a Professor of Pharmacology at the University of Pennsylvania, Philadelphia, Pa., with more than 30 years’ experience in both the academic and industrial sectors. He also is a member of the BioMotiv Advisory Board.

Dr. Molinoff previously served as the Chairman and A.N. Richards Professor of Pharmacology in the Department of Pharmacology at the University of Pennsylvania, where his research focused on the molecular pharmacology of receptors and signal recognition. As Vice Provost for Research he developed linkages between the university and industry to enable transfer of technologies from university laboratories for commercial application. He also managed elements of the research infrastructure relating to grants, human and animal research compliance, animal care, environmental health and conflict of interest and research misconduct. In this position, he provided leadership and coordination of multidisciplinary research programs and represented the university to local and regional constituencies. During his term, the University of Pennsylvania’s research enterprise managed more than $700 million in research awards.

Dr. Molinoff previously served as the Executive Vice President of Research and Development at Palatin Technologies and Vice President of Neuroscience and Genitourinary Drug Discovery for the Bristol-Meyers Squibb Pharmaceutical Research Institute. During his tenure, clinical candidates were identified for treatment of sleep disorders, schizophrenia, stroke, Parkinson’s disease, Alzheimer’s disease, incontinence and sexual dysfunction. He currently serves on boards of directors of several public and private companies.

Dr. Molinoff earned his undergraduate and medical degrees from Harvard University, Cambridge, Mass. He has authored or edited more than 230 papers in medical and scientific journals and six books and served on numerous editorial advisory boards.